Bone Biologics Co. (NASDAQ:BBLG) Short Interest Up 69.0% in June

Bone Biologics Co. (NASDAQ:BBLG) was the recipient of a large increase in short interest in the month of June. As of June 15th, there was short interest totalling 21,800 shares, an increase of 69.0% from the May 31st total of 12,900 shares. Approximately 4.2% of the shares of the company are short sold. Based on an average daily volume of 79,700 shares, the short-interest ratio is currently 0.3 days.

Bone Biologics Stock Performance

NASDAQ BBLG traded up $0.02 during midday trading on Friday, hitting $1.23. The company had a trading volume of 30,827 shares, compared to its average volume of 100,682. The firm has a fifty day simple moving average of $1.61 and a two-hundred day simple moving average of $2.59. Bone Biologics has a fifty-two week low of $1.13 and a fifty-two week high of $14.16.

Bone Biologics (NASDAQ:BBLG) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($1.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($7.60) by $6.29. Equities research analysts forecast that Bone Biologics will post -5.32 EPS for the current year.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.